Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 9/20 | 0.34 |
| ▸ | NR1H3 | Q13133 | 8/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | STS | P08842 | 1/20 | 0.32 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
| ▸ | F13A1 | P00488 | 1/20 | 0.31 |
| ▸ | TGM2 | P21980 | 1/20 | 0.31 |
| ▸ | TGM1 | P22735 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14857161 | 0.91 | NR1H2 (0.34) | NR1H2NR1H3PTPN1HSD11B1MEN1 | |
| SCHEMBL15388623 | 0.91 | NR1H2 (0.34) | NR1H2NR1H3PTPN1HSD11B1MEN1 | |
| SCHEMBL1662641 | 0.88 | PTPN1 (0.41) | NR1H2NR1H3PTPN1HSD11B1MEN1 | |
| SCHEMBL1662643 | 0.88 | PTPN1 (0.41) | NR1H2NR1H3PTPN1HSD11B1MEN1 | |
| SCHEMBL3557230 | 0.88 | PTPN1 (0.41) | NR1H2NR1H3PTPN1HSD11B1MEN1 | |
| SCHEMBL12248021 | 0.85 | NR1H2 (0.35) | NR1H2NR1H3PTPN1HSD11B1MEN1 | |
| SCHEMBL30305041 | 0.82 | NAMPT (0.41) | NR1H2NR1H3RORC | |
| SCHEMBL4032654 | 0.82 | NR1H2 (0.42) | NR1H2NR1H3STSRORC | |
| SCHEMBL4032657 | 0.82 | NR1H2 (0.42) | NR1H2NR1H3STSRORC | |
| SCHEMBL29280765 | 0.80 | PTPN1 (0.34) | NR1H2NR1H3PTPN1HSD11B1STS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110237636-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237636-A1 | Hepatitis C Virus Inhibitors | HAVCR2, EIF2AK2, MAVS | NR1H2 297/4885NR1H3 260/4885PTPN1 998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.